Acris Antibodies’ unique antibody offering complements our existing antibody portfolio, and expands our capabilities to better serve our customers for their research antibody needs
Rockville, MD (PRWEB) October 28, 2015
OriGene Technologies, Inc. (“OriGene”), an industry leader of genome wide products for research and diagnostic applications, announced today that it has acquired Acris Antibodies GmbH (“Acris Antibodies”), a provider of antibodies and other life science related products.
Acris Antibodies sells and distributes research antibodies and related life science products to research, diagnostic and biopharmaceutical customers worldwide. The company has 16 employees with operations in Germany and the United States.
“Acris Antibodies’ unique antibody offering complements our existing antibody portfolio, and expands our capabilities to better serve our customers for their research antibody needs,” said Donghui Ma, Ph.D., Sr. Vice President of OriGene Technologies. “We also see this acquisition as a great opportunity to meet the increasing demand from our European distributors and customers for a better and faster service, and also plan to leverage our global reach to bring Acris products to a larger customer base.”
In a related statement, Hans-Joachim Soll, Ph.D., General Manager and Founder of Acris Antibodies said, “We believe that the joined forces of Acris’ unique strength in the antibody market and EU presence and OriGene’s global reach will greatly enhance our ability to better meet customer needs for high quality antibodies”.
Acris Antibodies supplies more than 364,000 antibodies and scientific research products, and will be integrated into OriGene’s antibody business unit.
About OriGene Technologies Inc.
OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide. Empowered by the world's largest collections of gene-centric tools of cDNA clones, human proteins, antibodies and assays, OriGene has produced an extensive array of ultra-specific monoclonal antibodies called UltraMAB®, which offer a unique solution to the critical issue of antibody specificity, especially for diagnostic and therapeutic antibodies. For more information, visit http://www.OriGene.com.